Understanding Momentum Shifts in (ZIMV)
This article from Stock Traders Daily discusses understanding momentum shifts in Zimvie Inc. (ZIMV) based on AI-generated analysis. It outlines three distinct trading strategies (Position, Momentum Breakout, Risk Hedging) tailored for different risk profiles, and highlights key findings, signals, and support/resistance levels. The platform offers real-time signals, multi-timeframe analysis, and personalized alerts to registered users.
ZimVie to be acquired by Archimed for $19.00 per share in cash
This article announces that ZimVie will be acquired by Archimed for $19.00 per share in cash. The acquisition price represents a 51% premium over ZimVie's closing stock price on January 29, 2026. The transaction is expected to close in the first half of 2026.
Behavioral Patterns of ZIMV and Institutional Flows
This article analyzes Zimvie Inc. (NASDAQ: ZIMV) using AI models to generate trading strategies across different risk profiles and holding periods, focusing on institutional flows. It provides signal analysis, including support and resistance levels, and offers real-time trading signals for entry and exit points, risk-reward ratios, and multi-timeframe updates. The platform aims to add alpha, reduce beta, and control risk through sophisticated risk management parameters.
Liquidity Mapping Around (ZIMV) Price Events
This article from Stock Traders Daily discusses liquidity mapping around price events for Zimvie Inc. (NASDAQ: ZIMV). It highlights AI-generated institutional trading strategies tailored for different risk profiles, including position trading, momentum breakout, and risk hedging strategies. The analysis also provides multi-timeframe signal analysis with support and resistance levels.
$19.00 Per Share: ZimVie Becomes Private After ARCHIMED Acquisition; NASDAQ Delisted
ZimVie (NASDAQ: ZIMV) announced on October 20, 2025, that ARCHIMED completed its acquisition of the company, making ZimVie a privately held entity. Under the terms of the transaction, ARCHIMED acquired all outstanding ZimVie shares for $19.00 in cash per share, resulting in the delisting of ZimVie common stock from NASDAQ. This acquisition provides immediate liquidity to shareholders, aligning ZimVie with ARCHIMED's focus on accelerating growth in the dental implant market.
ARCHIMED completes acquisition of dental implant maker ZimVie
Investment firm ARCHIMED has completed its acquisition of dental implant maker ZimVie Inc. for $19.00 per share in cash, valuing ZimVie at approximately $536 million. The transaction, initially announced on July 20, 2025, led to ZimVie's delisting from NASDAQ after the stock delivered a 102% return over the prior six months. ZimVie, a global provider of dental implants and biomaterials with $443 million in annual revenue, will partner with healthcare-focused ARCHIMED to accelerate its growth in the dental implant market.
ZimVie Inc Completes Acquisition by ARCHIMED
ZimVie Inc. announced on October 20, 2025, that it has completed its acquisition by ARCHIMED, an investment firm specializing in healthcare industries. As a result, ZimVie has become a privately held company, and its common stock is no longer traded on NASDAQ; stockholders received $19.00 per share. This acquisition is expected to boost ZimVie's growth in the dental implant market with ARCHIMED's strategic and financial backing, despite past weak financial performance and technical indicators suggesting a potential pullback.
Dental Tech Leader ZimVie Gets Massive 99% Premium in $730M ARCHIMED Buyout Deal
ZimVie (Nasdaq: ZIMV), a dental implant market leader, has agreed to be acquired by ARCHIMED for approximately $730 million. Shareholders will receive $19.00 per share in cash, representing a 99% premium over the 90-day volume-weighted average price. The transaction, unanimously approved by ZimVie's Board, includes a 40-day "go-shop" period and is expected to close by year-end 2025, after which ZimVie will become a private company.
ZimVie Inc to be Acquired by ARCHIMED
ZimVie Inc. announced a definitive agreement to be acquired by ARCHIMED for $19.00 per share in cash, totaling approximately $730 million. This transaction represents a 99% premium over ZimVie’s 90-day volume-weighted average price and is expected to close by the end of 2025. Upon completion, ZimVie will become a privately held company and delisted from NASDAQ.
Latham & Watkins Advises ARCHIMED in US$730 Million Acquisition of ZimVie Inc.
Latham & Watkins LLP is representing ARCHIMED in its US$730 million acquisition of ZimVie Inc., a global life sciences leader in the dental implant market. ZimVie stockholders will receive US$19.00 in cash per share, and the transaction is expected to close by year-end 2025, after which ZimVie will become a privately held company. The multidisciplinary Latham & Watkins team is providing comprehensive legal advice across various practice areas for the deal.
ZIMVIE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of ZimVie Inc. - ZIMV
Kahn Swick & Foti, LLC (KSF), led by former Louisiana Attorney General Charles C. Foti, Jr., is investigating the proposed sale of ZimVie Inc. (NasdaqGS: ZIMV) to an affiliate of ARCHIMED. Shareholders are set to receive $19.00 in cash per share. KSF aims to determine if this consideration adequately values ZimVie and whether the process leading to the sale was fair.
ARCHIMED Completes Acquisition of ZimVie Inc. in Strategic Move to Enhance Dental Implant Solutions
ARCHIMED has completed its acquisition of ZimVie Inc., a leader in the dental implant market, for $19.00 per share in cash, effective October 20, 2025. This strategic move aims to accelerate ZimVie's growth and enhance its presence in the dental implant market, leveraging ARCHIMED's expertise and resources in the healthcare sector. Following the acquisition, ZimVie's stock will no longer be traded on NASDAQ.
ZimVie to be acquired by ARCHIMED in $730 million deal
ZimVie Inc. (NASDAQ:ZIMV), a dental implant market leader, announced its acquisition by healthcare investment firm ARCHIMED in an all-cash deal valued at approximately $730 million. Stockholders will receive $19.00 per share, a 99% premium over the 90-day volume-weighted average price. The transaction is expected to close by year-end 2025, after which ZimVie will become a private company.
ZimVie Inc. Enters Strategic Distribution Agreement with Osstem Implant to Expand Presence in China’s Dental Implant Market
ZimVie Inc. has announced a strategic distribution agreement with Osstem Implant Co., Ltd. to expand its presence in China's dental implant market, which is estimated to be over 10 million units annually. This partnership will give Osstem exclusive commercial responsibility for ZimVie's implant systems in China, leveraging Osstem's extensive distribution channels and clinical education programs. The collaboration aims to provide a broader product selection for customers and reinforce ZimVie’s focus on innovation and customer experience in the dental implant sector.
Latham And Cravath Steer $730M ZimVie Take-Private Deal
Law firms Latham & Watkins LLP and Cravath Swaine & Moore LLP are involved in a $730 million take-private deal for dental implant company ZimVie Inc. Healthcare investment firm ArchiMed is purchasing ZimVie, with Latham advising ArchiMed and Cravath advising ZimVie. This transaction highlights significant legal counsel in large-scale private equity acquisitions within the healthcare sector.
ZimVie to Announce Q2 Results July 30
ZimVie Inc. announced it will report financial results for the second quarter of 2025 on July 30, following a definitive agreement to be acquired by ARCHIMED for $19.00 per share. The transaction is expected to close by year-end 2025, after which ZimVie will become a privately held company and its shares will no longer be publicly traded on Nasdaq. Consequently, ZimVie will not host a Q2 conference call and has withdrawn its fiscal 2025 guidance.
ZimVie Announces Completion of its Acquisition by ARCHIMED
ZimVie, a global leader in the dental implant market, announced the completion of its acquisition by ARCHIMED, a healthcare-focused investment firm. As a result, ZimVie is now a privately held company, and its common stock no longer trades on the NASDAQ stock exchange. ZimVie stockholders received $19.00 in cash for each share of common stock.
ZimVie inks exclusive dental implant distro deal with Osstem in China
ZimVie has announced an exclusive dental implant distribution agreement with Osstem Implant Co. to expand its presence in the Chinese market. Osstem, a market leader in China, will have commercial responsibility for ZimVie's implant systems, offering a wider product selection to its customer base. This partnership leverages Osstem's extensive network and ZimVie's implant technology to enhance customer access and expand market reach.
ZimVie Inc. Enters Strategic Distribution Agreement with Osstem Implant to Expand Presence in China’s Dental Implant Market
ZimVie Inc. has announced a strategic distribution agreement with Osstem Implant Co., Ltd. to significantly expand its presence in China's rapidly growing dental implant market. This partnership grants Osstem, a market leader in China with extensive distribution channels, exclusive commercial responsibility for ZimVie's implant systems in the country. The collaboration aims to offer a wider range of products to customers and reinforce ZimVie’s commitment to innovation and enhancing the customer experience in the global dental implant sector.
ZimVie partners with Osstem Implant to expand in Chinese dental market
ZimVie Inc. has entered into a strategic distribution agreement with Osstem Implant Co., Ltd. to bolster its presence in the Chinese dental implant market. This partnership leverages Osstem's extensive distribution network across over 90 Chinese cities and ZimVie's high-quality implant systems. The announcement comes amidst other significant company news, including a merger agreement with ARCHIMED valued at approximately $730 million, which has influenced analyst ratings and stock performance.
EX-99.1
ZimVie Inc. (Nasdaq: ZIMV) announced a definitive agreement to be acquired by ARCHIMED, an investment firm, for $19.00 per share in an all-cash transaction. This represents a 99% premium over ZimVie's 90-day volume-weighted average price. The deal, valued at approximately $730 million, is expected to close by year-end 2025, after which ZimVie will become a privately held company.
Shareholder Alert: The Ademi Firm investigates whether ZimVie Inc. is obtaining a Fair Price for its Public Shareholders
The Ademi Firm is investigating ZimVie (NASDAQ: ZIMV) concerning a potential breach of fiduciary duty and other legal violations related to its transaction with ARCHIMED. Shareholders are set to receive $19.00 per share in cash, totaling approximately $730 million in enterprise value, but the firm is looking into whether this value is fair given that insiders will benefit substantially and the agreement includes a significant penalty for competing bids. The investigation aims to determine if the ZimVie board of directors is upholding its fiduciary duties to all shareholders.
ZIMV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of ZimVie Inc. Is Fair to Shareholders
Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of ZimVie Inc. (NASDAQ: ZIMV) to an affiliate of ARCHIMED for $19.00 in cash per share is fair to ZimVie shareholders. The firm is examining whether ZimVie and its board failed to obtain the best possible consideration, adequately assess ARCHIMED's offer, or disclose all material information related to the merger. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders.
ZimVie Expands Digital Dentistry in Japan
ZimVie Inc. (Nasdaq: ZIMV) has launched its RealGUIDE® Software Suite and Implant Concierge® service in Japan, significantly expanding its digital dentistry offerings in the APAC region's largest market. These services provide comprehensive, vertically integrated solutions for implant planning, surgical guidance, and restorative design, aiming to enhance practice efficiencies and improve patient care. The company emphasizes the growing importance of digital dentistry in an expanding implant market and seeks to leverage its offerings for continued growth in sophisticated markets like Japan.
ZimVie Inc. (ZIMV) stock price, news, quote and history
This page from Yahoo Finance provides an overview of ZimVie Inc. (ZIMV) stock information, including its presence on various stock exchanges with different ticker symbols and current prices. It also lists related news (though none are displayed) and presents general market data such as major index performance, top gainers, top losers, and most active stocks in the Singapore market.
Dental Implant Maker ZimVie Weighs Potential Sale
Dental implants manufacturer ZimVie Inc. (ZIMV) is considering various options, including a potential sale, following new takeover approaches. The company, based in Palm Beach, Florida, is working with an adviser to explore alternatives after receiving interest from a range of potential buyers, including both buyout firms and industry players.
ZimVie Closes Sale of Spine Business – Re-Named Highridge Medical
ZimVie has completed the sale of its Spine business to H.I.G. Capital for $375 million, with the acquired entity now operating as Highridge Medical. ZimVie will now focus solely on the dental industry, aiming to reduce debt and optimize its financial structure. Highridge Medical, led by experienced industry executives, generated approximately $400 million in sales in 2023 and is expected to invest in innovation to gain market share.
ZimVie begets Highridge Medical with completed spine business spinout
ZimVie has completed the spinout of its spine business to investment firm H.I.G. Capital for $375 million, creating the new independent company Highridge Medical. Highridge Medical will focus on spine-related medical devices, while ZimVie will continue as a pure-play dental business with an estimated $455 million in annual net sales from its dental offerings. ZimVie plans to use the proceeds to pay down $275 million in debt.
ZimVie launches Next-Generation TSX® dental Implant in Japan
ZimVie Inc. has launched its Next-Generation TSX® dental Implant in Japan, a strategically important market for the company. The TSX Implant is designed for immediate extraction and standard loading protocols, offering placement predictability and primary stability. This new implant is compatible with ZimVie’s digital workflows and existing tools, having already seen success since its U.S. debut in November 2022.
Zimmer Biomet completes spinoff of ZimVie spine, dental business
Zimmer Biomet has completed the spinoff of its spine and dental businesses, forming a new standalone public company named ZimVie, which began trading on the Nasdaq under the ticker "ZIMV". ZimVie anticipates achieving $1 billion in revenue in its first year, representing flat growth compared to its performance under Zimmer Biomet in 2021. This separation allows Zimmer Biomet to concentrate on its core orthopedic segments, while ZimVie aims to innovate and grow within the dental and spine markets with a collective $20 billion addressable opportunity.
Zimmer Biomet spinoff to be called ZimVie
Zimmer Biomet announced that its planned spinoff of its spine and dental businesses will be named ZimVie, a name symbolizing the new company's roots and future. The new company will be headquartered in Westminster, Colorado, and has announced key leadership appointments, including Richard J. Heppenstall as EVP and CFO. The creation of ZimVie is on track to close in mid-2022.
